A Phase I Trial for R/R MetAstatic DLL3+ Cancers Utilizing Armored CAR T Cells (ARMADA)

Memorial Sloan Kettering Cancer Center

Summary

The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: Participant Inclusion: Collection of T cells (Part A) * History of DLL3+ neuroendocrine tumors * Includes patients with histologically confirmed SCLC, as well other advanced neuroendocrine tumors (NETs), including large cell neuroendocrine carcinomas (LCNECs), gastroenteropancreatic NETs (GEP-NETs), laryngeal NETs, genitourinary (GU) tract NETs, neuroendocrine prostate cancers (NEPCs), gynecological tract NETs, neuroblastomas, salivary NETs, glioblastoma multiforme, skin NETs, NETs of unknown primary, or other tumor confirmed positive for DLL3 by IHC * Any disease st…

Locations (7)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey
schoenfa@mskcc.org 646-608-4042
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey
schoenfa@mskcc.org 646-608-4042
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey
schoenfa@mskcc.org 646-608-4042
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited Protocol Activities)
Commack, New York
schoenfa@mskcc.org 646-608-4042
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York
schoenfa@mskcc.org 646-608-4042
Memorial Sloan Kettering Cancer Center (All protocol activities)
New York, New York
schoenfa@mskcc.org 646-608-4042

Summary

Eligibility

Interventions

Locations (7)